In a bold stride toward revolutionizing the biotechnology landscape, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has officially opened its newly expanded corporate headquarters in Warren, New Jersey. The state-of-the-art facility, fully funded by the company’s Founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., marks a pivotal moment in Tevogen’s mission to advance immunotherapy through artificial intelligence (AI).
The doubled footprint of the headquarters centralizes the company’s research and development (R&D), regulatory affairs, and rapidly growing Tevogen.AI teams under one roof, fostering unprecedented collaboration and operational efficiency. This strategic move underscores Tevogen Bio’s commitment to leveraging cutting-edge AI to accelerate the development of precision T cell therapies for infectious diseases, cancers, and neurological disorders, while prioritizing affordability and accessibility for patients worldwide.
Tevogen Bio, a clinical-stage specialty immunotherapy company, has long been at the forefront of harnessing CD8+ cytotoxic T lymphocytes (CTLs) through its proprietary ExacTcell™ platform. This technology enables the development of off-the-shelf, genetically unmodified T cell therapeutics designed to target specific disease markers while preserving healthy cells.
The company’s innovative approach has already shown promise, with positive safety data reported from its proof-of-concept clinical trial for TVGN 489, an investigational T cell therapy targeting high-risk COVID-19 patients and Long COVID. Notably, TVGN 489 advanced from discovery to clinical testing in just 18 months, a timeline significantly faster than the industry average of 10–12 years, demonstrating Tevogen’s ability to expedite drug development.
The new headquarters, completed ahead of schedule, is a testament to Tevogen’s forward-thinking vision. By centralizing cross-functional teams, including executive leadership, regulatory affairs, and R&D—previously based in Philadelphia—the facility enhances collaboration and streamlines workflows. A key feature of the expansion is the dedicated space for Tevogen.AI, the company’s artificial intelligence initiative launched in October 2023. Headed by Chief Information Officer Mittul Mehta, Tevogen.AI is designed to integrate advanced machine learning and predictive modeling into the ExacTcell™ platform, significantly enhancing target identification and pre-clinical processes. This AI-driven approach aims to reduce drug development timelines by up to 30% and substantially lower costs, which typically range from $1–3 billion per drug.
Dr. Ryan Saadi emphasized the transformative potential of this initiative, stating, “This expansion will provide the infrastructure needed to support two of our evolving initiatives, Tevogen.AI and Generics & Biosimilars. From advancing domestic pharmaceutical manufacturing to harnessing the power of AI in drug discovery, these programs reflect our commitment to building a more resilient and accessible healthcare system.” The CEO’s personal financial contribution to the headquarters’ build-out and first-year operations ensures that no additional burden is placed on the company or its shareholders, highlighting leadership’s dedication to fiscal responsibility and strategic growth.
Tevogen.AI’s collaboration with Microsoft, through the Microsoft for Startups program, has been instrumental in advancing its AI capabilities. This partnership provides access to Microsoft’s cutting-edge AI tools, cloud computing infrastructure, and scientific expertise, enabling Tevogen to develop proprietary algorithms like PredicTcell™ and AdapTcell™. PredicTcell™, a suite of AI algorithms, predicts immunologically active peptide-T cell receptor interactions, enhancing the precision of immunotherapy treatments. AdapTcell™ decodes interactions between human leukocyte antigens (HLA) and T cells, opening new therapeutic avenues. These technologies, backed by a terabyte-scale database analyzing millions of protein-peptide interactions, have already shown impact, notably in identifying targets for Human Papillomavirus (HPV) to launch Tevogen’s oncology pipeline with TVGN 920.
Mittul Mehta, a Microsoft alum with over 20 years of IT experience, highlighted the partnership’s significance during a recent fireside chat at the J.P. Morgan Healthcare Conference. “We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models,” Mehta said. He emphasized the importance of “clean” and “annotated” datasets, a sentiment echoed by Microsoft’s Global Chief Medical Officer, Dr. David Rhew, who noted, “AI is like a powerful engine. It needs clean, curated data as fuel.” The collaboration also incorporates robust data governance and privacy-preserving techniques, such as federated learning, ensuring secure handling of sensitive data.
Tevogen’s AI efforts extend beyond its own pipeline, with ambitions to support other biotech companies in expediting drug discovery, manufacturing, and patient access. The company has filed two AI-related patent applications, including “Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models,” strengthening its intellectual property portfolio, which includes three granted patents and 21 pending patents worldwide. This robust IP strategy, free from third-party licensing agreements, positions Tevogen as a leader in the biotech industry.
The expanded headquarters also supports Tevogen’s Generics & Biosimilars initiative, aimed at enhancing domestic pharmaceutical manufacturing. By integrating AI-driven innovation with scalable production, Tevogen projects cumulative revenues of $10–14 billion for its oncology division and $18–22 billion for its specialty care pipeline, including an expansion to serve patients aged 65 and older. These ambitious forecasts reflect the company’s confidence in its disruptive business model, which prioritizes patient equity and accessibility.
Dr. Neal Flomenberg, Tevogen’s Chief Scientific Officer, underscored the adaptability of the ExacTcell™ platform, stating, “Our technology can create a spectrum of CTL products targeting a wide range of viruses, including HPV. The integration of AI allows us to analyze large datasets across the genome, yielding faster and more accurate target identification.” This capability is critical for addressing unmet medical needs in large patient populations, particularly in virology, oncology, and neurology.
The new headquarters, formerly occupied by CAPTRUST, also has the capacity to support potential new business units as Tevogen diversifies its portfolio. A formal ribbon-cutting ceremony is planned, with local officials, employees, and community partners expected to attend, further cementing Tevogen’s role as a community-driven innovator in Warren, New Jersey.
Tevogen’s leadership, comprising industry veterans from companies like Johnson & Johnson, Sanofi, and MetLife, believes that sustainable success in healthcare hinges on advanced science and innovative business models. The company’s commitment to transparency is evident in its plans to provide regular updates to shareholders, with further details expected at the upcoming J.P. Morgan Healthcare Conference in January 2026.
As the biotech industry faces challenges like lengthy development timelines and high costs, Tevogen Bio’s AI-driven approach offers a promising solution. By combining its ExacTcell™ platform with Tevogen.AI’s predictive capabilities, the company is poised to deliver life-changing therapies faster and more cost-effectively. The new headquarters serves as a physical embodiment of this vision, uniting science, technology, and a patient-centric mission to reshape the future of immunotherapy.
